Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.
$ESPR
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/20/2024 | $2.50 | Neutral → Underperform | BofA Securities |
| 1/3/2024 | Buy → Neutral | BofA Securities | |
| 11/20/2023 | Neutral | JP Morgan | |
| 8/1/2023 | Under Perform → Market Perform | Northland Capital | |
| 6/15/2023 | $1.25 → $4.00 | Underperform → Buy | BofA Securities |
| 3/16/2023 | $1.00 | Market Perform → Under Perform | Northland Capital |
| 3/16/2023 | $8.00 → $1.50 | Neutral → Underperform | BofA Securities |
| 3/7/2023 | $6.50 → $7.00 | Underperform → Neutral | Credit Suisse |
Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy
Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy
Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for appro
– Total Revenue Increased 186% Year-over-Year to $73.8 Million withU.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 Million and Allocated Proceeds for Early, Discounted Payoff and Termination of Oberland Capital Revenue Interest Facility – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported finan
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be arc
BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50
BofA Securities downgraded Esperion Therapeutics from Buy to Neutral
JP Morgan resumed coverage of Esperion Therapeutics with a rating of Neutral
ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior position of Senior Director, Financial Planning and Analysis, effective as of today. He will serve as a member of the executive management team and report to Sheldon Koenig, President and Chief Executive Officer. "We are thrilled to have Ben take on this expanded role on the Esperion leadership team with his promotion to CFO," said Sheldon Koenig, President and CEO of Esperion. "Ben has made significant contributions since joining the company in 2020, supporting our finance organization during a tra
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion's Board of Directors. Mr. Carroll will serve as a Class I director with a term expiring at the 2023 annual meeting of stockholders. "On behalf of the Esperion team and our directors, I am excited to welcome Marty as Chairperson of the Esperion Board. With his significant experience, Marty will provide additional leadership and strategic guidance to our Board as we continue to commercialize our medicines and advance our pipeline," said Sheldon Koenig, president and chief executive officer of Esperion. "Marty's expertise will be critical
ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting of stockholders. Mr. Rocamboli fills the newly created vacancy resulting from Dr. Mark McGovern's retirement from the Board. "On behalf of the Esperion team and our directors, I am very pleased to welcome Stephen to the Esperion Board. Stephen's extensive experience as a senior business and legal executive for multiple public life science organizations will be a great asset for Esperion as we continue to commercialize our medicines and grow our pipeline," said Sheldon Koenig, president and ch
Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16 price target.
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
S-8 - Esperion Therapeutics, Inc. (0001434868) (Filer)
10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)
8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic
ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024. Featured ScienceBempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New Insights from the CLEAR Outcomes TrialFeatured Science: Vascular Outcomes in the SpotlightNovember 18, 2024, 8 - 9:15 a.m. CSTPresenter: Marc P. Bonaca, MD, MPH, FAHA, FACC Poster PresentationsLiver Steatosis and Liver Fibrosis Predict Major Adverse Cardiovascular Events in the CLEAR Outcom
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for appro